세계의 피부암 치료제 시장 보고서(2025년)

Skin Cancer Drugs Global Market Report 2025

US $ 4,490 ￦ 6,265,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,056,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,846,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

피부암 치료제 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 CAGR 11.8%로 84억 7,000만 달러로 성장합니다. 예측 기간 중의 성장은 면역 요법의 발전, 정밀의료 및 바이오마커 연구, 환자 교육 및 인식 제고 프로그램, 세계 공동 연구, 치료 옵션의 확대 등에 기인하는 것으로 보입니다. 예측 기간 중 주요 동향으로는 효능을 높이기 위한 병용요법, 맞춤형 의료 접근법 채택, 국소 치료법 개발, 조기 발견 및 예방에 대한 강조, 새로운 약물전달 시스템 탐색 등이 있습니다.

피부암의 유병률이 크게 증가함에 따라 이 질환을 치료할 수 있는 약품에 대한 수요가 증가하고 있습니다. 미국 암 협회는 2022년에 약 99,780건의 흑색종 피부암이 새로 진단되어 연간 약 7,650명이 사망할 것으로 추정된다고 보고했습니다. 이러한 피부암 환자의 급증은 피부암 치료제에 대한 수요 증가에 기여하고 있으며, 그 결과 시장을 촉진하고 있습니다.

개인의 일광욕과 태닝 증가는 향후 수년간 피부암 치료제 시장의 성장을 가속할 것으로 예상됩니다. 일광욕은 개인이 햇빛 아래에서 보내는 시간을 의미하며, 피부와 건강 전반에 긍정적인 영향과 부정적인 영향을 미칠 수 있습니다. 일광화상은 햇빛이나 기타 자외선(UV) 광원에 장시간 노출되어 피부가 검게 변색되거나 변색되는 것을 말합니다. 피부 질환, 특히 피부암 증가는 치료법의 발전과 인식 증가와 함께 피부암 치료제 시장의 확대에 기여하고 있습니다. 예를 들어 호주 정부 기관인 호주 통계청에 따르면 2024년 3월, 15세 이상 호주인 4명 중 1명(24.6%)이 30분 동안 햇빛을 쬐면 '그을림만 있고 태닝은 없습니다'고 응답했습니다. 또한 15세 이상 5명 중 2명(38.1%)은 2023-24년 늦봄부터 늦여름까지 대부분의 날에 SPF30 이상의 자외선 차단제를 사용한다고 답했습니다. 따라서 선탠과 태닝에 대한 관심이 높아지면서 피부암 치료제 시장의 성장을 촉진하고 있습니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, Covid, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 피부암 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
• 최종 용도 산업의 분석
• 세계의 피부암 치료제 시장 : 성장률 분석
• 세계의 피부암 치료제 시장 실적 : 규모와 성장, 2019-2024
• 세계의 피부암 치료제 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 피부암 치료제 TAM(Total Addressable Market)

제6장 시장 세분화

• 세계의 피부암 치료제 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 광선각화증(AK)
• 기저세포암(BCC)
• 편평 상피암(SCC)
• 악성 흑색종
• 세계의 피부암 치료제 시장 : 약제 클래스별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 화학요법
• 면역치료
• 표적 약제 및 기타 약제
• 세계의 피부암 치료제 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 병원
• 암연구 센터
• 클리닉
• 세계의 피부암 치료제 시장, 광선각화증(AK)의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 냉동요법
• 외용약
• 광역학요법(PDT)
• 레이저 치료
• 세계의 피부암 치료제 시장, 기저세포암(BCC)의 유형별 서브 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 외과적 절제
• 모즈 현미경 수술
• 방사선 치료
• 국소 요법
• 세계의 피부암 치료제 시장, 편평 상피암(SCC)의 유형별 서브 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 외과적 절제
• 냉동요법
• 전기 외과수술과 소파술
• 방사선 치료
• 세계의 피부암 치료제 시장, 흑색종의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 외과적 절제
• 면역치료
• 표적치료
• 화학요법과 방사선 요법

제7장 지역별·국가별 분석

• 세계의 피부암 치료제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 피부암 치료제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 피부암 치료제 시장 : 경쟁 구도
• 피부암 치료제 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Meda Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 대기업과 혁신적 기업

• Novartis International AG
• Sanofi SA
• Bristol Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Mylan N.V.
• Daiichi Sankyo Company Limited
• Bausch Health Companies Inc.
• Valeant Pharmaceuticals
• Sun Pharmaceutical Industries Ltd
• Ipsen Pharma
• Varian Medical Systems Inc.

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 피부암 치료제 시장 2029 : 새로운 기회를 제공하는 국가
• 피부암 치료제 시장 2029 : 새로운 기회를 제공하는 부문
• 피부암 치료제 시장 2029 : 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁사 전략

제36장 부록

KSA

영문 목차

영문목차

Skin cancer drugs are a category of chemotherapy medications employed in the treatment of skin cancer, a condition characterized by abnormal proliferation of skin cells. While frequently appearing on sun-exposed skin, skin cancer can also develop on areas less exposed to sunlight. Various types of skin cancer include actinic keratoses, basal cell carcinoma, squamous cell carcinoma, and melanoma. Examples of drugs used in skin cancer treatment encompass 5-FU, Aldara, and Efudex.

The primary classifications of skin cancer drugs include actinic keratoses (AK), basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. Actinic keratoses manifest as broad, rough skin patches that may transform into cancerous growths, typically emerging on sun-exposed areas such as the face, scalp, hands, and chest, with a higher incidence in fair-skinned individuals. Terms such as solar keratosis and senile keratosis are used interchangeably to describe this condition. The various drug classes employed in skin cancer treatment encompass chemotherapy, immunotherapy, targeted agents, and other drugs, with applications extending to hospitals, cancer research centers, and clinics.

The skin cancer drugs market research report is one of a series of new reports from The Business Research Company that provides skin cancer drugs market statistics, including skin cancer drugs industry global market size, regional shares, competitors with a skin cancer drugs market share, detailed skin cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the skin cancer drugs industry. This skin cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The skin cancer drugs market size has grown rapidly in recent years. It will grow from $4.76 billion in 2024 to $5.42 billion in 2025 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to increasing incidence of skin cancer, sun exposure and uv radiation concerns, advancements in diagnostics, changing demographics and aging population, regulatory approvals and clinical research.

The skin cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $8.47 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to immunotherapy advancements, precision medicine and biomarker research, patient education and awareness programs, global collaborations in research, expanding therapeutic options. Major trends in the forecast period include combination therapies for enhanced effectiveness, adoption of personalized medicine approaches, development of topical treatments, increased focus on early detection and prevention, exploration of novel drug delivery systems.

The significant increase in skin cancer prevalence is fueling the demand for drugs to address this condition. To cater to the growing cases of skin cancer, there is a continuous development of innovative drugs. In 2022, The American Cancer Society reported that around 99,780 new cases of melanoma skin cancer were diagnosed, with an estimated 7,650 deaths annually. This surge in skin cancer cases is contributing to an elevated demand for skin cancer drugs, consequently propelling the market.

The rise in sun exposure and tanning among individuals is anticipated to drive the growth of the skin cancer drug market in the coming years. Sun exposure refers to the time an individual spends in sunlight, which can have both positive and negative effects on skin and overall health. Tanning is the darkening or discoloration of the skin due to prolonged exposure to sunlight or other sources of ultraviolet (UV) radiation. Increasing cases of skin diseases, particularly skin cancer, along with advancements in treatment options and growing awareness, are contributing to the expansion of the skin cancer drug market. For instance, in March 2024, according to the Australian Bureau of Statistics, an Australian government agency, one in four (24.6%) Australians aged 15 and over reported they would 'just burn and not tan' after 30 minutes of sun exposure. Additionally, two in five (38.1%) people aged 15 and over used SPF30 or higher sunscreen most days during late spring and summer 2023-24. Therefore, rising sun exposure and tanning trends are driving the growth of the skin cancer drug market.

Companies operating in the Skin Cancer Market are increasingly opting for Strategic Alliances with other market players. Such alliances are seen as beneficial in enhancing R&D capabilities, expediting new drug development, and strengthening competitive positions. For instance, Leo Pharma strategically aligned with PellePharm to jointly develop a drug for treating Gorlin syndrome, a rare form of skin cancer. MorphoSys collaborated with LEO Pharma to develop antibodies for skin cancer treatment. Pfizer entered a strategic alliance with Merck KGaA to produce an innovative drug for skin cancer.

Major companies in the skin cancer drugs market are placing emphasis on securing product approvals to better cater to existing demand. The increase in product approvals results from a combination of scientific advancements, regulatory adjustments, market demands, and patient advocacy. For example, in March 2023, Incyte Corporation, a US-based pharmaceutical company specializing in skin cancer drugs, announced FDA approval for Zynyz (Retifanlimab-Dlwr) in the treatment of metastatic or recurrent Merkel cell carcinoma (MCC). Zynyz, a monoclonal antibody targeting programmed death receptor-1 (PD-1), obtained expedited FDA approval based on tumor response rate and duration of response (DOR). Its continued clearance for this use is contingent upon confirmation of therapeutic benefits in confirmatory studies.

In April 2022, Regeneron, a US-based biotechnology company, acquired Checkmate Pharmaceuticals for $250 million. This acquisition expands Regeneron's immuno-oncology research efforts, focusing on potential approaches for challenging-to-treat cancers, particularly in the domain of skin cancer drugs. Checkmate Pharmaceuticals, a US-based company in the skin cancer drugs sector, aligns with Regeneron's strategic objectives.

Major companies operating in the skin cancer drugs market include Pfizer Inc., Meda Pharmaceuticals, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Mylan N.V., Daiichi Sankyo Company Limited, Bausch Health Companies Inc., Valeant Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Ipsen Pharma, Varian Medical Systems Inc., Kyowa Kirin Co. Ltd., QIAGEN N.V., Elekta AB, Cannabis Science Inc., LEO Pharma A/S, Aqua Pharmaceuticals, iCAD Inc., AB Science, Cellceutix Corporation, Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Seattle Genetics Inc.

North America was the largest region in the skin cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the global skin cancer drugs market during the forecast period. The regions covered in the skin cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the skin cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The skin cancer drugs market consists of sales of vismodegib (Erivedge) and sonidegib (Odomzo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Skin Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on skin cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for skin cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The skin cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Actinic Keratoses (AK); Basal cell carcinoma (BCC); Squamous cell carcinoma (SCC); Melanoma
• 2) By Drug Class: Chemotherapy; Immunotherapy; Targeted Agents & Other Drugs
• 3) By End Users: Hospitals; Cancer Research Centers; Clinics
• Subsegments:
• 1) By Actinic Keratoses (AK): Cryotherapy Treatments; Topical Medications; Photodynamic Therapy (PDT); Laser Therapy
• 2) By Basal Cell Carcinoma (BCC): Surgical Excision; Mohs Micrographic Surgery; Radiation Therapy; Topical Therapies
• 3) By Squamous Cell Carcinoma (SCC): Surgical Excision; Cryosurgery; Electrosurgery and Curettage; Radiation Therapy
• 4) By Melanoma: Surgical Excision; Immunotherapy; Targeted Therapy; Chemotherapy and Radiation
• Companies Mentioned: Pfizer Inc.; Meda Pharmaceuticals; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Skin Cancer Drugs Market Characteristics

3. Skin Cancer Drugs Market Trends And Strategies

4. Skin Cancer Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Skin Cancer Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Skin Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Skin Cancer Drugs Market Growth Rate Analysis
• 5.4. Global Skin Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Skin Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Skin Cancer Drugs Total Addressable Market (TAM)

6. Skin Cancer Drugs Market Segmentation

• 6.1. Global Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Actinic Keratoses (AK)
• Basal cell carcinoma (BCC)
• Squamous cell carcinoma (SCC)
• Melanoma
• 6.2. Global Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Immunotherapy
• Targeted Agents & Other Drugs
• 6.3. Global Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Cancer Research Centers
• Clinics
• 6.4. Global Skin Cancer Drugs Market, Sub-Segmentation Of Actinic Keratoses (AK), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cryotherapy Treatments
• Topical Medications
• Photodynamic Therapy (PDT)
• Laser Therapy
• 6.5. Global Skin Cancer Drugs Market, Sub-Segmentation Of Basal Cell Carcinoma (BCC), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgical Excision
• Mohs Micrographic Surgery
• Radiation Therapy
• Topical Therapies
• 6.6. Global Skin Cancer Drugs Market, Sub-Segmentation Of Squamous Cell Carcinoma (SCC), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgical Excision
• Cryosurgery
• Electrosurgery and Curettage
• Radiation Therapy
• 6.7. Global Skin Cancer Drugs Market, Sub-Segmentation Of Melanoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgical Excision
• Immunotherapy
• Targeted Therapy
• Chemotherapy and Radiation

7. Skin Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Skin Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Skin Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Skin Cancer Drugs Market

• 8.1. Asia-Pacific Skin Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Skin Cancer Drugs Market

• 9.1. China Skin Cancer Drugs Market Overview
• 9.2. China Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Skin Cancer Drugs Market

• 10.1. India Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Skin Cancer Drugs Market

• 11.1. Japan Skin Cancer Drugs Market Overview
• 11.2. Japan Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Skin Cancer Drugs Market

• 12.1. Australia Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Skin Cancer Drugs Market

• 13.1. Indonesia Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Skin Cancer Drugs Market

• 14.1. South Korea Skin Cancer Drugs Market Overview
• 14.2. South Korea Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Skin Cancer Drugs Market

• 15.1. Western Europe Skin Cancer Drugs Market Overview
• 15.2. Western Europe Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Skin Cancer Drugs Market

• 16.1. UK Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Skin Cancer Drugs Market

• 17.1. Germany Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Skin Cancer Drugs Market

• 18.1. France Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Skin Cancer Drugs Market

• 19.1. Italy Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Skin Cancer Drugs Market

• 20.1. Spain Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Skin Cancer Drugs Market

• 21.1. Eastern Europe Skin Cancer Drugs Market Overview
• 21.2. Eastern Europe Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Skin Cancer Drugs Market

• 22.1. Russia Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Skin Cancer Drugs Market

• 23.1. North America Skin Cancer Drugs Market Overview
• 23.2. North America Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Skin Cancer Drugs Market

• 24.1. USA Skin Cancer Drugs Market Overview
• 24.2. USA Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Skin Cancer Drugs Market

• 25.1. Canada Skin Cancer Drugs Market Overview
• 25.2. Canada Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Skin Cancer Drugs Market

• 26.1. South America Skin Cancer Drugs Market Overview
• 26.2. South America Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Skin Cancer Drugs Market

• 27.1. Brazil Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Skin Cancer Drugs Market

• 28.1. Middle East Skin Cancer Drugs Market Overview
• 28.2. Middle East Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Skin Cancer Drugs Market

• 29.1. Africa Skin Cancer Drugs Market Overview
• 29.2. Africa Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Skin Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Skin Cancer Drugs Market Competitive Landscape
• 30.2. Skin Cancer Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Meda Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Skin Cancer Drugs Market Other Major And Innovative Companies

• 31.1. Novartis International AG
• 31.2. Sanofi SA
• 31.3. Bristol Myers Squibb Company
• 31.4. AstraZeneca PLC
• 31.5. GlaxoSmithKline plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Boehringer Ingelheim International GmbH
• 31.9. Mylan N.V.
• 31.10. Daiichi Sankyo Company Limited
• 31.11. Bausch Health Companies Inc.
• 31.12. Valeant Pharmaceuticals
• 31.13. Sun Pharmaceutical Industries Ltd
• 31.14. Ipsen Pharma
• 31.15. Varian Medical Systems Inc.

32. Global Skin Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Skin Cancer Drugs Market

34. Recent Developments In The Skin Cancer Drugs Market

35. Skin Cancer Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Skin Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Skin Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Skin Cancer Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료